The EMA anticipates that the ability to access scientific advice will foster innovation among medical device manufacturers.

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

1 Christoffersen M et al. Transthyretin Tetramer Destabilization and Increased Mortality in the General Population. JAMA ...

USD/JPY is extending gains above 153.50 in Wednesday's Asian trading. The Japanese Yen continues losing ground amid latest ...

GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...

The EUR/JPYhits a multi-week low on the strong yen. It hit a low of 155.49 and is currently trading around 156.95.The ...

EUR/USD traders found the buy button and bolstered the pair back above the 1.0350 level on Tuesday. Fiber broke out of a three-day down streak. Still, momentum remains limited, and the pair continues ...

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

The euro has gapped lower to kick off the trading week, as we continue to see a lot of volatility in this pair. <li /> As it is likely t ...

USD/JPY traders eye Japan’s machine tool orders and US CPI data for market direction. Will softer inflation revive Fed rate ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.